Novozymes raises 2026 outlook after H1 sales growth
Novozymes said H1 organic sales grew 8% and adjusted EPS excluding PPA amortization rose 9% to €1.09, while it lifted full-year organic sales growth guidance to 7%-8%.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.